• Hongjoong Kim Chief Excutive Officer President

    We have a mission to develop qualified drugs to treat patients suffering from their diseases.
    EnhancedBio is making a difference for the therapeutic benefit in favor of patients.
    I am very proud of our strong team for their contribution and commitment for our goal.
    I am confident that we will become a global leading biotechnology company.

    MORE INFO
  • Hyunjung Choi Chief Clinical Officer

    New study drug development should be based on patient-oriented and involve strong moral characteristic.
    Being an expert and professional is fundamental.
    And more importantly, we highly value solid work ethics.
    I am very proud to be a member of EnhancedBio; having patient-oriented as our top priority.
    I strongly believe that our promising pipelines will help save patients suffering from their disease in the near future.

    MORE INFO
  • Hunsoon Jung Chief Technology Officer

    I am pleased to see consistent progress with our drug program.
    In aspect of the basic research and platform discovery,
    I believe that we are making a difference and this will be highly valued by cancer patients in the future.
    I hope that all our effort will help improve quality of life for everyone including patients and their loved ones.
    I am very enthusiastic to make this drive.

    MORE INFO
  • Kyoungsun Ji Director of Management Division

    EnhancedBio is an extraordinary biotech company in Korea. We are composed of many outstanding talents here. This is certainly one team with a clear, distinct vision and great potential and foresight.
    Without a doubt, what we have done and achieved are very valuable. EnhancedBio is committed to ambitiously make continued progress and see positive outcomes in the future.

    MORE INFO
  • Jason Hur Director of Project Management

    I joined EnhancedBio in 2020 with strong confidence. Coupled strongly with the talent here we are certainly capable of making changes in which these changes will be valued in many aspects of health care for the future.
    New drug development is like a long journey with many challenges ahead.
    EnhancedBio is highly committed to overcoming and always keeping abreast with challenges.
    We are focused on improving the lives of patients by developing innovative drugs.
    I feel honored to be a member of EnhancedBio.

    MORE INFO
  • Bongsu Park Director of Regulatory Affairs

    I sincerely feel proud of our progress and development that we are witnessing here in EnhancedBio. We do have the strength and capability to identify unmet needs of cancer patients and lead the way to successful launch of therapeutic agents. By succeeding in the development of world-class anti-cancer drugs, we will positively contribute to improve the quality of life for patients suffering from cancer-related diseases

    MORE INFO
Management
  • Hongjoong Kim

    CEO & President

    Hongjoong holds a PhD from the Medical School, Newcastle University, U.K.Hongjoong is a senior drug development professional with more than 25 years’ experience in the life sciences industry. He has served in senior leadership positions in large international corporations and biotech companies prior to founding EnhancedBio.





    “We have a mission to develop qualified drugs to treat patients suffering from their diseases. EnhancedBio is making a difference for the therapeutic benefit in favor of patients. I am very proud of our strong team for their contribution and commitment for our goal. I am confident that we will become a global leading biotechnology company.”  

  • Hyunjung Choi

    Chief Clinical Officer

    Hyunjung Choi is the chief clinical officer and also the vice president in EnhancedBio. She has around 15 years of professional experience in the health care and pharmaceutical industry prior to joining EnhancedBio. During this period, she successfully led a number of clinical studies from phase I to IV; primarily large-scale global and multi-national studies. One of her strength is a diversity of therapeutic experience; covering oncology, CNS, Cardiovascular, Urology, OBGYN, Endocrinology, Nephrology, Respiratory, Diabetics and Immunology.


    “New study drug development should be based on patient-oriented and involve strong moral characteristic. Being an expert and professional is fundamental. And more importantly, we highly value solid work ethics. I am very proud to be a member of EnhancedBio; having patient-oriented as our top priority. I strongly believe that our promising pipelines will help save patients suffering from their disease in the near future.”

  • Hunsoon Jung

    Chief Technology Officer

    Dr. Hunsoon is an executive director and the CTO (Chief Technology Officer).
    While being responsible for leading our R&D center, his primary focus is to develop pipelines & technologies and to advance them from fundamental research into clinical assets. His core strength includes but is not limited to the development of candidate product and process, supply chain, manufacturing, quality and CMC strategy, and non-clinical studies for IND. He has nearly 20 years of experience in the field of bioscience and pharmacology. During his doctoral studies at Seoul National University, Department of Pharmacy, he successfully established a drug discovery of siRNA therapeutics for cancer diseases. He has dedicated to advancing the innovative solution with one hope in his mind; patients being benefited from our drug development at the earliest opportunity.


    “I am pleased to see consistent progress with our drug program. In aspect of the basic research and platform discovery, I believe that we are making a difference and this will be highly valued by cancer patients in the future. I hope that all our effort will help improve quality of life for everyone including patients and their loved ones. I am very enthusiastic to make this drive.”

  • Kyoungsun Ji

    Director of Management Division

    Prior to joining EnhancedBio, Kyoungsun Ji worked for Doosan Corp - a major corporation in Korea with experience in excess of 20 years.
    He has extensive experience and a strong skillset in general management, business management & strategy, and finance management
    In EnhancedBio, Kyoungsun plays an essential role especially in division coordination & support, finance management, and IPO & holdings related matters.


    “EnhancedBio is an extraordinary biotech company in Korea. We are composed of many outstanding talents here. This is certainly one team with a clear, distinct vision and great potential and foresight.
    Without a doubt, what we have done and achieved are very valuable. EnhancedBio is committed to ambitiously make continued progress and see positive outcomes in the future.”

  • Jason Hur

    Director of Project Management

    Jason Hur brings over 15 years of experience in the health care and pharmaceutical industries.
    Before joining EnhancedBio, Jason was a project manager at a global-leading CRO where he led several multi-national studies with global pharma and biotech companies.
    He joined EnhancedBio in 2020 as a senior project manager and currently serves as a director of project management.
    Jason’s primary role is to lead the Clinical Operations Team (COT) and to supervise clinical trial development.


    “I joined EnhancedBio in 2020 with strong confidence. Coupled strongly with the talent here we are certainly capable of making changes in which these changes will be valued in many aspects of health care for the future.
    New drug development is like a long journey with many challenges ahead.
    EnhancedBio is highly committed to overcoming and always keeping abreast with challenges.
    We are focused on improving the lives of patients by developing innovative drugs.
    I feel honored to be a member of EnhancedBio.”

  • Bongsu Park

    Director of Regulatory Affairs

    Bongsu Park is the director of regulatory affairs (RA) in EnhancedBio. He is primarily responsible for IND-enabling regulatory dossier as well as CTD-readiness package. From a regulatory angle, Bongsu provides oversight and leadership for non-clinical studies and manages all regulatory-related matters. With over 15 years of professional experience in toxicology and pharmacology, Bongsu acts as the bridge to close the gap between non-clinical to clinical stage.


    “I sincerely feel proud of our progress and development that we are witnessing here in EnhancedBio. We do have the strength and capability to identify unmet needs of cancer patients and lead the way to successful launch of therapeutic agents. By succeeding in the development of world-class anti-cancer drugs, we will positively contribute to improve the quality of life for patients suffering from cancer-related diseases”

Previous member
Next member